Herborium Group Partners with Hut Group, the UK's Leading Online Retail Platform, to Take Advantage of $3 Billion Market for

Herborium Group Partners with Hut Group, the UK's Leading Online Retail Platform, to Take Advantage of $3 Billion Market for Acne Therapeutics  Company sales of its one of kind Botanical Therapeutic® for acne, AcnEase®, grows 52% in the first quarter of 2013.  FORT LEE, N.J., June 13, 2013 (GLOBE NEWSWIRE) -- via PRWEB - Herborium Group, Inc., (OTC Pink: HBRM) http://www.herborium.com, a Botanical Therapeutics® Company has announced today that it has partnered with the leading online retail platform in the UK, The Hut Group, to market AcnEase®, an all botanical therapeutic for acne, to consumers in the UK, EU and Australia. Since 2010 when The Hut Group raised £14 million to fund its growth, its sales rose 600%. AcnEase® sales in the first quarter of 2013 grew 52% in comparison to the first quarter of 2012.  The global revenues in the acne market are $3 billion, and a steady growth of the market for acne therapeutics is expected to continue to 2018 with the USA and EU leading the demand with over 120 million acne sufferers. In addition to its presence on The Hut Group platform through Mankind.co.uk, the no. 1 UK male grooming site, LookFantastic.com and BeautyExpert.co.uk, leading women online retailers, as of April of 2013, AcnEase® has also been featured on MySkin.com, one of the most popular online retail platforms in the USA targeting the premier beauty and skincare markets.  "We are very excited about the growth of revenues and expansion of distribution channels for AcnEase®," commented Dr. Agnes P. Olszewski, Herborium CEO and Chairwomen. "With the established growth path for AcnEase®, we can now focus on the marketing and sales of our new products, making 2013 a top revenue year for Herborium," concluded Dr. Olszewski.  About Herborium Group, Inc. Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sells its products in the USA and Europe. For more information, please visit http://www.herborium.com, http://www.acnease.com and http://www.herboriumsh.com.  One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.  For more information, please inquire: Investorsrelations(at)herborium(dot)com.  This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2013/6/prweb10828073.htm  CONTACT: Herborium Group, Inc.          Investor Relations          investorsrelations@herborium.com          201-849-4431